{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,18]],"date-time":"2026-10-18T22:40:43Z","timestamp":1792363243083,"version":"4.4.0"},"reference-count":35,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,6,24]],"date-time":"2026-06-24T00:00:00Z","timestamp":1782259200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T00:00:00Z","timestamp":1788912000000},"content-version":"vor","delay-in-days":77,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Malar J"],"DOI":"10.1186\/s12936-026-05982-1","type":"journal-article","created":{"date-parts":[[2026,6,24]],"date-time":"2026-06-24T16:37:38Z","timestamp":1782319058000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Adherence to 14-day primaquine treatment for radical cure of Plasmodium vivax and mixed malaria patients treated at health centers in Yilmana Densa district, Ethiopia: a community-based cross-sectional study"],"prefix":"10.1186","volume":"25","author":[{"given":"Eshetie Alelign","family":"Tsega","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ayenew Molla","family":"Lakew","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Habtamu Alebachew","family":"Tegegne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gizachew Abeza","family":"Getahun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ejigu Gebeye","family":"Zeleke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,24]]},"reference":[{"key":"5982_CR1","unstructured":"Ministry of Health. Surveillance, Monitoring and Evaluation Manual for Malaria Elimination in Ethiopia. Addis Abeba2017."},{"key":"5982_CR2","unstructured":"Ministry of Health. Case ManagementImplementation Manual For Malaria Elimination in Ethiopia. second ed. Addis Abeba2022."},{"key":"5982_CR3","unstructured":"Ministry of Health. National Malaria Guideline. Fifth ed. Addis Abeba2022."},{"key":"5982_CR4","doi-asserted-by":"crossref","unstructured":"Alemayehu A. Biology and epidemiology of malaria recurrence: Implication for control and elimination. Infectious Diseases Annual Volume 2022: IntechOpen; 2022.","DOI":"10.5772\/intechopen.108888"},{"key":"5982_CR5","doi-asserted-by":"publisher","DOI":"10.1186\/s40794-022-00185-3","volume":"8","author":"K Habtamu","year":"2022","unstructured":"Habtamu K, Petros B, Yan G. Plasmodium vivax: the potential obstacles it presents to malaria elimination and eradication. Trop Dis Travel Med Vaccin. 2022;8:27.","journal-title":"Trop Dis Travel Med Vaccin"},{"key":"5982_CR6","unstructured":"Ministry of Health. NATIONAL MALARIA ELIMINATION STRATEGIC PLAN (2024\/25\u20132026\/27). Addis Abeba2023. 89 p."},{"key":"5982_CR7","volume-title":"WHO guidelines for malaria, 3 June 2022","author":"Organization WH","year":"2022","unstructured":"Organization WH. WHO guidelines for malaria, 3 June 2022. World Health Organization; 2022."},{"key":"5982_CR8","doi-asserted-by":"publisher","first-page":"306","DOI":"10.1186\/s12936-023-04725-w","volume":"22","author":"P Mehdipour","year":"2023","unstructured":"Mehdipour P, Rajasekhar M, Dini S, Zaloumis S, Abreha T, Adam I, et al. Effect of adherence to primaquine on the risk of Plasmodium vivax recurrence: a WorldWide Antimalarial Resistance Network systematic review and individual patient data meta-analysis. Malar J. 2023;22:306.","journal-title":"Malar J"},{"key":"5982_CR9","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/1471-2458-13-637","volume":"13","author":"T Ketema","year":"2013","unstructured":"Ketema T, Bacha K. Plasmodium vivax associated severe malaria complications among children in some malaria endemic areas of Ethiopia. BMC Public Health. 2013;13:1\u20137.","journal-title":"BMC Public Health"},{"key":"5982_CR10","unstructured":"Tadesse FG, Chali W, Ejigu LA, Abdo M, Kassa FA, Gebremichael M, et al. The Contribution of Recurrent Plasmodium Vivax Infections to the Human Infectious Reservoir for Malaria; a Longitudinal Study from Ethiopia."},{"key":"5982_CR11","volume-title":"WHO Guideline for Malaria","author":"World Health Organization","year":"2023","unstructured":"World Health Organization. WHO Guideline for Malaria. Geneva: Switzerland; 2023."},{"key":"5982_CR12","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13071-021-05064-y","volume":"14","author":"PL Aung","year":"2021","unstructured":"Aung PL, Soe MT, Soe TN, Oo TL, Aung PP, Khin A, et al. The acceptability of targeted mass treatment with primaquine for local elimination of vivax malaria in a northern Myanmar township: a mixed-methods study. Parasit Vectors. 2021;14:1\u201311.","journal-title":"Parasit Vectors"},{"key":"5982_CR13","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/1475-2875-10-351","volume":"10","author":"D Fernando","year":"2011","unstructured":"Fernando D, Rodrigo C, Rajapakse S. Primaquine in vivax malaria: an update and review on management issues. Malar J. 2011;10:1\u201312.","journal-title":"Malar J"},{"key":"5982_CR14","doi-asserted-by":"crossref","unstructured":"Milligan R, Daher A, Villanueva G, Bergman H, Graves PM. Primaquine alternative dosing schedules for preventing malaria relapse in people with Plasmodium vivax. Cochrane Database of Systematic Reviews. 2020.","DOI":"10.1002\/14651858.CD012656.pub3"},{"key":"5982_CR15","unstructured":"Ministry of Health. Annual national performance report. Addis Abeba; 2021."},{"key":"5982_CR16","doi-asserted-by":"publisher","DOI":"10.1186\/s12936-024-04874-6","volume":"23","author":"S Tesfaye","year":"2024","unstructured":"Tesfaye S, Yesuf A. Trend analysis of malaria surveillance data in West Wallaga, West Oromia, Ethiopia: a framework for planning and elimination. Malar J. 2024;23:52.","journal-title":"Malar J"},{"key":"5982_CR17","volume-title":"WHO guidelines for malaria, 14 March 2023","author":"Organization WH","year":"2023","unstructured":"Organization WH. WHO guidelines for malaria, 14 March 2023. World Health Organization; 2023."},{"key":"5982_CR18","doi-asserted-by":"publisher","DOI":"10.1186\/s12936-024-04884-4","volume":"23","author":"D Lek","year":"2024","unstructured":"Lek D, Tsai Y-C, Hirano J, Sovannaroth S, Bunreth V, Vonn P, et al. Radical cure for Plasmodium vivax malaria after G6PD qualitative testing in four provinces in Cambodia, results from Phase I implementation. Malar J. 2024;23:56.","journal-title":"Malar J"},{"key":"5982_CR19","doi-asserted-by":"crossref","unstructured":"Rahmalia A, Poespoprodjo JR, Landuwulang CU, Ronse M, Kenangalem E, Burdam FH, et al. Adherence to 14-day radical cure for P. vivax malaria in Papua, Indonesia: a mixed-methods study. 2022.","DOI":"10.21203\/rs.3.rs-1760602\/v1"},{"key":"5982_CR20","doi-asserted-by":"publisher","DOI":"10.3329\/jhpn.v27i1.3313","volume":"27","author":"N Khantikul","year":"2009","unstructured":"Khantikul N, Butraporn P, Kim HS, Leemingsawat S, Tempongko MSB, Suwonkerd W. Adherence to antimalarial drug therapy among vivax malaria patients in northern Thailand. J Health Popul Nutr. 2009;27:4.","journal-title":"J Health Popul Nutr"},{"key":"5982_CR21","doi-asserted-by":"publisher","DOI":"10.3390\/pathogens12121392","volume":"12","author":"MS Hossain","year":"2023","unstructured":"Hossain MS, Matin MA, Ferdous N-EN, Hasan A, Sazed SA, Neogi AK, et al. Adherence to anti-malarial treatment in malaria endemic areas of Bangladesh. Pathogens. 2023;12:1392.","journal-title":"Pathogens"},{"key":"5982_CR22","doi-asserted-by":"publisher","DOI":"10.4269\/ajtmh.2010.09-0521","volume":"82","author":"KP Grietens","year":"2010","unstructured":"Grietens KP, Soto V, Erhart A, Ribera JM, Toomer E, Tenorio A, et al. Adherence to 7-day primaquine treatment for the radical cure of P. vivax in the Peruvian Amazon. Am Soc Trop Med Hyg. 2010;82:1017.","journal-title":"Am Soc Trop Med Hyg"},{"key":"5982_CR23","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13756-020-00846-y","volume":"9","author":"MG Gebrekidan","year":"2020","unstructured":"Gebrekidan MG, Gebremedhin GB, Gebregiorgis YS, Gezehegn AA, Weldearegay KT. Artemether\u2013lumefantrin treatment adherence among uncomplicated Plasmodium falciparum malaria patients, visiting public health facilities in AsgedeTsimbla district, Tigray, Ethiopia: a cross-sectional study. Antimicrob Resist Infect Control. 2020;9:1\u201312.","journal-title":"Antimicrob Resist Infect Control"},{"key":"5982_CR24","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/1475-2875-10-355","volume":"10","author":"EA Pereira","year":"2011","unstructured":"Pereira EA, Ishikawa EA, Fontes CJ. Adherence to Plasmodium vivax malaria treatment in the Brazilian Amazon Region. Malar J. 2011;10:1\u20136.","journal-title":"Malar J"},{"key":"5982_CR25","doi-asserted-by":"publisher","DOI":"10.1186\/s12936-025-05365-y","volume":"24","author":"H Getachew","year":"2025","unstructured":"Getachew H, Habtamu K, Abossie A, Demissew A, Tsegaye A, Degefa T, et al. Effect of low-dose primaquine treatment on Plasmodium vivax recurrence and transmission-blocking activity in southwest Ethiopia: a longitudinal cohort study. Malar J. 2025;24:125.","journal-title":"Malar J"},{"key":"5982_CR26","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12936-021-03702-5","volume":"20","author":"B Adhikari","year":"2021","unstructured":"Adhikari B, Awab GR, von Seidlein L. Rolling out the radical cure for vivax malaria in Asia: a qualitative study among policy makers and stakeholders. Malar J. 2021;20:1\u201315.","journal-title":"Malar J"},{"key":"5982_CR27","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1186\/s12936-023-04443-3","volume":"22","author":"S Saita","year":"2023","unstructured":"Saita S, Roobsoong W, Khammaneechan P, Sukchan P, Lawpoolsri S, Sattabongkot J, et al. Community acceptability, participation, and adherence to mass drug administration with primaquine for Plasmodium vivax elimination in Southern Thailand: a mixed methods approach. Malar J. 2023;22:17.","journal-title":"Malar J"},{"key":"5982_CR28","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12936-018-2472-5","volume":"17","author":"K Saravu","year":"2018","unstructured":"Saravu K, Tellapragada C, Kulavalli S, Xavier W, Umakanth S, Brahmarouphu G, et al. A pilot randomized controlled trial to compare the effectiveness of two 14-day primaquine regimens for the radical cure of vivax malaria in South India. Malar J. 2018;17:1\u201311.","journal-title":"Malar J"},{"key":"5982_CR29","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pgph.0003615","volume":"5","author":"AT Ansari","year":"2025","unstructured":"Ansari AT, Aung KK, Win HH, Beau C, Nu B, Soe NL, et al. A mixed methods study investigating factors affecting adherence to Plasmodium vivax malaria primaquine radical cure regimens among migrants along the Myanmar-Thailand border. PLOS Glob Public Health. 2025;5:e0003615.","journal-title":"PLOS Glob Public Health"},{"key":"5982_CR30","doi-asserted-by":"publisher","first-page":"5198010","DOI":"10.1155\/2019\/5198010","volume":"2019","author":"AR Oduro","year":"2019","unstructured":"Oduro AR, Chatio S, Beeri P, Anyorigiya T, Baiden R, Adongo P, et al. Adherence to Dihydroartemisinin-Piperaquine Treatment among Patients with Uncomplicated Malaria in Northern Ghana. J Trop Med. 2019;2019:5198010.","journal-title":"J Trop Med"},{"key":"5982_CR31","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.1004255","volume":"21","author":"DJ Price","year":"2024","unstructured":"Price DJ, Nekkab N, Monteiro WM, Villela DA, Simpson JA, Lacerda MV, et al. Tafenoquine following G6PD screening versus primaquine for the treatment of vivax malaria in Brazil: a cost-effectiveness analysis using a transmission model. PLoS Med. 2024;21:e1004255.","journal-title":"PLoS Med"},{"key":"5982_CR32","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0148627","volume":"11","author":"S Dierickx","year":"2016","unstructured":"Dierickx S, Gryseels C, Mwesigwa J, O\u2019Neill S, Bannister-Tyrell M, Ronse M, et al. Factors associated with non-participation and non-adherence in directly observed mass drug administration for malaria in The Gambia. PLoS ONE. 2016;11:e0148627.","journal-title":"PLoS ONE"},{"key":"5982_CR33","doi-asserted-by":"crossref","unstructured":"Mac\u00edas Saint-Gerons D, Rodovalho S, Barros Dias \u00c1L, Lacerda Ulysses de Carvalho A, Beratarrechea A, Monteiro WM, et al. Strengthening therapeutic adherence and pharmacovigilance to antimalarial treatment in Manaus, Brazil: a multicomponent strategy using mHealth. Malaria Journal. 2022;21:28.","DOI":"10.1186\/s12936-022-04047-3"},{"key":"5982_CR34","doi-asserted-by":"publisher","DOI":"10.1186\/s12936-023-04578-3","volume":"22","author":"A Rahmalia","year":"2023","unstructured":"Rahmalia A, Poespoprodjo JR, Landuwulang CU, Ronse M, Kenangalem E, Burdam FH, et al. Adherence to 14-day radical cure for Plasmodium vivax malaria in Papua, Indonesia: a mixed-methods study. Malar J. 2023;22:162.","journal-title":"Malar J"},{"key":"5982_CR35","doi-asserted-by":"publisher","DOI":"10.1186\/s12936-021-03732-z","volume":"20","author":"A Fehr","year":"2021","unstructured":"Fehr A, Nieto-Sanchez C, Muela J, Jaiteh F, Ceesay O, Maneh E, et al. From informed consent to adherence: factors influencing involvement in mass drug administration with ivermectin for malaria elimination in The Gambia. Malar J. 2021;20:198.","journal-title":"Malar J"}],"container-title":["Malaria Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12936-026-05982-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12936-026-05982-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12936-026-05982-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T01:16:10Z","timestamp":1788916570000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12936-026-05982-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,24]]},"references-count":35,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["5982"],"URL":"https:\/\/doi.org\/10.1186\/s12936-026-05982-1","relation":{},"ISSN":["1475-2875"],"issn-type":[{"value":"1475-2875","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,24]]},"assertion":[{"value":"26 August 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 June 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 June 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The study was approved by an Institutional Review Board (IRB) of the University of Gondar, College of Medicine and Health Science, Institute of Public Health (Reference number: \/IPH\/3110\/2024). A support letter was obtained from the Amhara Public Health Institute, the North Gojjam Zone Health Department, and the Yilmana Densa district health office. Written informed consent was obtained from each study participant after clearly explaining the purpose, benefits, and risks of the study. For participants younger than 18\u00a0years of age, written consent was obtained from their parents or caregivers, and assent was obtained from the participants. The data were anonymized, and the data collection tool did not include personal identifiers such as names or addresses; instead, unique codes were used to keep participants' confidentiality. Participants were informed of their full right to withdraw from the study at any stage. Health education regarding the risks of non-adherence and the importance of completing the PQ treatment course was provided to non-adherent participants. Furthermore, participants with leftover pills were counseled to complete the remaining doses.","order":1,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"326"}}